Background <p>Multiple myeloma (MM) is a hematologic malignancy characterized by a high relapse rate despite recent therapeutic advances. B-cell maturation antigen (BCMA) and G protein-coupled receptor class C group 5 member D (GPRC5D) are two well-validated targets, with Food and Drug Administration-approved bispecific antibodies demonstrating clinical efficacy; however, their effectiveness is often limited by antigen escape and immune evasion.</p> Methods…
YMN-V115: a novel humanized BCMA/GPRC5D/CD3 trispecific antibody in relapsed/refractory multiple myeloma
Journal for ImmunoTherapy of Cancer | | Li, J., Lu, Q., Zhu, Z., Wang, X., Chen, Y., Zhang, Z., Yu, Z., Wang, Z., Chen, Y., Xie, H., Yang, N., Lu, H., Niu, T., Nie, C., Tong, A., Li, H.
Topics: blood-cancer, new-technology, research
Read the full article at Journal for ImmunoTherapy of Cancer